BAX protein-immunoreactivity in midbrain neurons of Parkinson's disease patients

Brain Research Bulletin

Volumn 62, Issue 1, 2003, Pages 55-61

  Horowitz, Judith M ^a   Pastor, Danielle M ^b   Goyal, Alpna ^b   Kar, Subrata ^b   Ramdeen, Navindra ^b   Hallas, Brian H ^b   Torres, German ^b  

^a MEDAILLE COLLEGE   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Apoptosis; Degeneration; Dopamine; Human brain; Inclusions

Indexed keywords

PROTEIN BAX;

APOPTOSIS; ARTICLE; CELL INCLUSION; CELL LABELING; CYTOPLASM; DENDRITE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; MALE; MESENCEPHALON; MOLECULAR WEIGHT; NERVE CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA;

EID: 0142257924     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2003.08.005     Document Type: Article

References (31)

1. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555.
2. Cregan S.P., MacLaurin J.G., Craig C.G., Robertson G.S., Nicholson D.W., Park D.S., Slack R.S. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J. Neurosci. 19:1999;7860-7869.
3. Duan W., Zhang Z., Gash D.M., Mattson M.P. Participation of prostate response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann. Neurol. 46:1999;587-597.
4. Dunnet S.B., Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature. 399:1999;A32-A39.
5. El-Agnaf O., Jakes R., Curran M., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D., Wallace A. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FASEB Lett. 440:1998;71-75.
6. Galloway P.G., Mulvihill P., Perry G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am. J. Pathol. 140:1992;809-822.
7. Galvin J.E., Lee V.M., Schmidt M.L., Tu P.H., Iwatsubo T., Trojanowski J.Q. Pathobiology of the Lewy body. Adv. Neurol. 80:1994;313-324.
8. Gross A., Jockel J., Wei M.C., Korsmeyer S.J. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 17:1998;3878-3885.
9. Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C., Reed J.C. Humanin peptide suppresses apoptosis by interfering with BAX activation. Nature. 423:2003;456-460.
10. Hartman A., Michael P.P., Troadec J.D., Mouatt-Prigent A., Faucheux B.A., Ruberg M., Agid Y., Hisrch E.C. Is Bax a mitochondrial mediator in apoptosis death of dopaminergic neurons in Parkinson's disease? J. Neurochem. 76:2001;1785-1793.
11. Horowitz J.M., Myers J., Vernace V.A., Stachowiak M.K., Torres G. Spatial distribution, cellular integration and stage development of Parkin protein in Xenopus brain. Dev. Brain Res. 126:2001;31-41.
12. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell. 105:2001;891-902.
13. Jellinger K.A. Cell death mechanisms in Parkinson's disease. J. Neural. Transm. 107:2002;1-29.
14. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44:1998;S72-S84.
15. Jiao Y., Sun Z., Lee T., Fusco F., Kimble T., Meade C., Cuthbertson S., Reiner A. A simple and sensitive antigen retrieval method for free-floating and slide-mounted tissue sections. J. Neurosci. Methods. 93:1999;149-162.
16. Krajewski S., Krajewska M., Shabaik A., Miyashita T., Wang H.G., Reed J.C. Immunohistochemical determination of in vivo distribution of BAX, a dominant inhibitor of Bcl2. Am. J. Pathol. 145:1994;1323-1336.
17. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. 1:2000;120-129.
18. Mattson M.P., Duan W. Apoptotic biochemical cascades in synaptic compartments: roles in adaptive plasticity and neurodegenerative disorders. J. Neurosci. Res. 58:1999;152-166.
19. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, BAX, that accelerates programmed cell death. Cell. 74:1993;609-619.
20. Saito M., Korsmeyer S.J., Schlesinger P.H. BAX-dependent transport of cytochrome c reconstituted in pure liposomes. Nat. Cell Biol. 2:2000;553-555.
21. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
22. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-267.
23. Sugimoto T., Xiao C., He Y.H., Ichikawa H. Bax protein-like immunoreactivity in primary sensory and hypothalamic neurons of adult rats. Neurosci. Lett. 215:1996;37-40.
24. Tatton N.A. Increased caspase 3 and BAX immunoreactivity accompany nuclear GAPDN translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166:2000;29-43.
25. Tatton W.G., Chalmers-Redman R., Brown D., Tatton N.A. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53:2003;561-570.
26. Torres G., Lee S., Rivier C. Ontogeny of the rat hypothalamic nitric oxide synthase and colocalization with neuropeptides. Mol. Cell. Neurosci. 4:1993;155-163.
27. Tortosa A., Lopez E., Ferrer I. Bcl-2 and Bax proteins in Lewy bodies from patients with Parkinson's disease and diffuse Lewy body disease. Neurosci. Lett. 238:1997;78-80.
28. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. PNAS. 98:2001;2837-2842.
29. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 22:1999;51-61.
30. Yin X.M., Oltvai Z.N., Korsmeyer S.J. BH1 and BH2 domains of Bcl2 are required for inhibition of apoptosis and heterodimerization with BAX. Nature. 369:1994;321-323.
31. Zhang Y., Dawson V.L., Dawson T.M. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 7:2000;240-250.